Skip to main content


We provide news, expert interviews, and educational resources to help you keep up with the latest developments in rheumatology

Conference coverage

ACR Convergence 2022

Medicine Matters rheumatology is covering the ACR Convergence 2022 meeting, bringing you news on the latest research. Browse now


Dapagliflozin may warrant further investigation for SLE

Dapagliflozin deserves further study as an add-on therapy for reducing renal and cardiovascular risk in patients with systemic lupus erythematosus, suggest preliminary trial findings. Read more

Have the ORAL Surveillance results changed rheumatology practice?

Following publication of the ORAL Surveillance trial, Richard Conway and Kevin Winthrop discuss the impact of the findings on JAK inhibitor prescribing, how regulatory recommendations compare in Europe and the USA, and whether the risks seen with tofacitinib represent a class effect.

IN FOCUS | JAK inhibitors

Close up of young woman taking in pill

18-10-2022 | Psoriatic arthritis | News

Support for JAK inhibitors as ‘drug of choice’ for patients with PsA and significant joint disease

JAK inhibitors show promise for the treatment of moderate-to-severe psoriasis and psoriatic arthritis, finds a systematic review and meta-analysis of more than 6000 patients.

IN FOCUS | COVID-19 & rheumatic disease

Doctor with stethoscope and glowing coronavirus cell - medicine and innovation concept.

24-10-2022 | COVID-19 | News

Prophylactic antivirals may help prevent symptomatic COVID-19 in rituximab-treated patients

Pre-exposure prophylaxis with tixagevimab and cilgavimab may be an effective strategy to prevent symptomatic SARS-CoV-2 infection among people with rheumatic diseases treated with rituximab, suggest findings from a real-world study.

IN FOCUS | Inflammatory arthritis

Simple 3d scene representing arrows, that hit targets with blackvision - target concept

28-11-2022 | Rheumatoid arthritis | News

Treatment goals in late-onset RA should match those for younger patients

People with late-onset rheumatoid arthritis have a similar likelihood of achieving remission as those with earlier-onset disease, indicating that treatment goals should be the same in both populations, researchers report.

IN FOCUS | Gout and crystal arthropathies

Man with painful and swollen right foot due to gout inflammation (symbolic image with model)

04-08-2022 | Gout | News

Gout flares linked to temporary increase in cardiovascular risk

Gout flares are associated with an increased risk for cardiovascular events in the following 120 days, study findings suggest.

IN FOCUS | Lupus

Close up of medical disposable syringe and vial

14-11-2022 | ACR 2022 | Conference coverage | News

Phase 3 trial supports add-on telitacicept for SLE

Addition of the recombinant fusion protein telitacicept to standard care may reduce disease activity and is well tolerated in people with systemic lupus erythematosus, research suggests.

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox